Logo

NanoString: Don Kania

Oct 31, 2019

NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.

Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.